Abliva AB (publ) (ABLI.ST)
SEK 0.42
(-0.83%)
SEK 0.42
(-0.83%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -96.54 Million SEK | -7.35% |
| 2022 | -83.19 Million SEK | 32.63% |
| 2021 | -123.48 Million SEK | -105.56% |
| 2020 | -60.07 Million SEK | 22.06% |
| 2019 | -77.07 Million SEK | -5.06% |
| 2018 | -73.36 Million SEK | -3.2% |
| 2017 | -71.08 Million SEK | 1.42% |
| 2016 | -72.11 Million SEK | -14.88% |
| 2015 | -62.76 Million SEK | -38.7% |
| 2014 | -45.25 Million SEK | -302.51% |
| 2013 | 22.34 Million SEK | 235.44% |
| 2012 | -16.49 Million SEK | -67.18% |
| 2011 | -9.86 Million SEK | -128.33% |
| 2010 | -4.32 Million SEK | -175.65% |
| 2009 | -1.56 Million SEK | 1.93% |
| 2008 | -1.59 Million SEK | -30.3% |
| 2007 | -1.22 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -25.41 Million SEK | -35.41% |
| 2024 Q1 | -19 Million SEK | 22.94% |
| 2023 Q2 | -21.44 Million SEK | -32.22% |
| 2023 FY | -89.3 Million SEK | -7.35% |
| 2023 Q1 | -16.21 Million SEK | 9.03% |
| 2023 Q3 | -32.93 Million SEK | -53.63% |
| 2023 Q4 | -24.66 Million SEK | 25.11% |
| 2022 Q2 | -18.27 Million SEK | 15.2% |
| 2022 FY | -83.19 Million SEK | 32.63% |
| 2022 Q4 | -17.82 Million SEK | 30.21% |
| 2022 Q1 | -21.55 Million SEK | 41.55% |
| 2022 Q3 | -25.54 Million SEK | -39.75% |
| 2021 Q1 | -21.45 Million SEK | -62.89% |
| 2021 Q3 | -34.85 Million SEK | -14.98% |
| 2021 Q4 | -36.86 Million SEK | -5.79% |
| 2021 FY | -123.48 Million SEK | -105.56% |
| 2021 Q2 | -30.31 Million SEK | -41.3% |
| 2020 Q3 | -10.07 Million SEK | 50.4% |
| 2020 FY | -60.07 Million SEK | 22.06% |
| 2020 Q4 | -13.16 Million SEK | -30.77% |
| 2020 Q2 | -20.3 Million SEK | -22.85% |
| 2020 Q1 | -16.52 Million SEK | 39.29% |
| 2019 FY | -77.07 Million SEK | -5.06% |
| 2019 Q3 | -15.28 Million SEK | 26.35% |
| 2019 Q1 | -13.8 Million SEK | 31.4% |
| 2019 Q4 | -27.22 Million SEK | -78.09% |
| 2019 Q2 | -20.75 Million SEK | -50.31% |
| 2018 Q3 | -15.07 Million SEK | 40.09% |
| 2018 Q2 | -25.16 Million SEK | -93.66% |
| 2018 Q1 | -12.99 Million SEK | 12.92% |
| 2018 FY | -73.36 Million SEK | -3.2% |
| 2018 Q4 | -20.13 Million SEK | -33.53% |
| 2017 FY | -71.08 Million SEK | 1.42% |
| 2017 Q4 | -14.92 Million SEK | -16.63% |
| 2017 Q3 | -12.79 Million SEK | 42.23% |
| 2017 Q2 | -22.14 Million SEK | -4.3% |
| 2017 Q1 | -21.23 Million SEK | -42.85% |
| 2016 FY | -72.11 Million SEK | -14.88% |
| 2016 Q1 | -10.93 Million SEK | -151.28% |
| 2016 Q4 | -14.86 Million SEK | 56.53% |
| 2016 Q3 | -34.19 Million SEK | -182.12% |
| 2016 Q2 | -12.11 Million SEK | -10.8% |
| 2015 Q3 | -54.05 Million SEK | -252.73% |
| 2015 FY | -62.76 Million SEK | -38.7% |
| 2015 Q4 | 21.33 Million SEK | 139.46% |
| 2015 Q1 | -14.71 Million SEK | 15.67% |
| 2015 Q2 | -15.32 Million SEK | -4.12% |
| 2014 Q2 | -14.09 Million SEK | -42.95% |
| 2014 FY | -45.25 Million SEK | -302.51% |
| 2014 Q1 | -9.86 Million SEK | -206.18% |
| 2014 Q4 | -17.45 Million SEK | -353.91% |
| 2014 Q3 | -3.84 Million SEK | 72.72% |
| 2013 Q4 | 9.28 Million SEK | 239.2% |
| 2013 FY | 22.34 Million SEK | 235.44% |
| 2013 Q3 | -6.67 Million SEK | -337.16% |
| 2013 Q2 | -1.52 Million SEK | 68.62% |
| 2013 Q1 | -4.86 Million SEK | 9.15% |
| 2012 Q2 | -4.13 Million SEK | -44.61% |
| 2012 Q3 | -4.16 Million SEK | -0.73% |
| 2012 Q4 | -5.35 Million SEK | -28.68% |
| 2012 FY | -16.49 Million SEK | -67.18% |
| 2012 Q1 | -2.85 Million SEK | -7.09% |
| 2011 Q2 | -3.18 Million SEK | -108.21% |
| 2011 Q4 | -2.66 Million SEK | -7.19% |
| 2011 FY | -9.86 Million SEK | -128.33% |
| 2011 Q1 | -1.52 Million SEK | -6.01% |
| 2011 Q3 | -2.48 Million SEK | 21.88% |
| 2010 Q3 | -1.5 Million SEK | -78.32% |
| 2010 Q1 | -535.14 Thousand SEK | -20.23% |
| 2010 Q4 | -1.44 Million SEK | 3.94% |
| 2010 FY | -4.32 Million SEK | -175.65% |
| 2010 Q2 | -842.31 Thousand SEK | -57.4% |
| 2009 Q2 | -423.63 Thousand SEK | -12.17% |
| 2009 Q3 | 321.65 Thousand SEK | 175.93% |
| 2009 Q4 | -445.08 Thousand SEK | -238.38% |
| 2009 FY | -1.56 Million SEK | 1.93% |
| 2009 Q1 | -377.66 Thousand SEK | 0.0% |
| 2008 FY | -1.59 Million SEK | -30.3% |
| 2007 FY | -1.22 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 61.223% |
| Ziccum AB (publ) | -21.56 Million SEK | -347.811% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -488.671% |
| BioArctic AB (publ) | 252.64 Million SEK | 138.216% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -11325.799% |
| Mendus AB (publ) | -100.65 Million SEK | 4.076% |
| Genovis AB (publ.) | 54.22 Million SEK | 278.054% |
| Intervacc AB (publ) | -93.57 Million SEK | -3.173% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -522.408% |
| Active Biotech AB (publ) | -46.48 Million SEK | -107.702% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 636.11% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -74.221% |
| Aptahem AB (publ) | -10.1 Million SEK | -855.47% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 69.97% |
| Kancera AB (publ) | -65.04 Million SEK | -48.439% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 28.279% |
| Fluicell AB (publ) | -26.87 Million SEK | -259.195% |
| Saniona AB (publ) | -81.06 Million SEK | -19.099% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -680.438% |
| Biovica International AB (publ) | -126.07 Million SEK | 23.419% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -127.145% |
| AcouSort AB (publ) | -17.48 Million SEK | -452.113% |
| Xintela AB (publ) | -57.23 Million SEK | -68.678% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 70.275% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -2654.579% |
| OncoZenge AB (publ) | -15.9 Million SEK | -507.144% |
| Amniotics AB (publ) | -29.07 Million SEK | -232.088% |
| 2cureX AB (publ) | -36.36 Million SEK | -165.512% |
| CombiGene AB (publ) | -36.3 Million SEK | -165.935% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -559.481% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 74.883% |
| Camurus AB (publ) | 532.35 Million SEK | 118.136% |
| Corline Biomedical AB | -1.78 Million SEK | -5299.776% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 46.589% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -131.624% |
| I-Tech AB | 24.43 Million SEK | 495.122% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 87.755% |
| Cyxone AB (publ) | -21.66 Million SEK | -345.723% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 8.887% |
| Biosergen AB | -27.26 Million SEK | -254.11% |
| Cantargia AB (publ) | -290.01 Million SEK | 66.71% |
| NextCell Pharma AB | -43.17 Million SEK | -123.635% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 46.589% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -464.731% |
| Nanologica AB (publ) | -69.96 Million SEK | -37.999% |
| SynAct Pharma AB | -224.49 Million SEK | 56.993% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -118.553% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -303.051% |
| LIDDS AB (publ) | -40.67 Million SEK | -137.37% |
| Lipum AB (publ) | -37.25 Million SEK | -159.161% |
| BioInvent International AB (publ) | -369.94 Million SEK | 73.902% |
| Alzinova AB (publ) | -16.52 Million SEK | -484.36% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 61.906% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -1410.155% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 16.098% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -379.408% |
| Simris Alg AB (publ) | -36.63 Million SEK | -163.54% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 34.127% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 68.898% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 12.952% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -734.757% |